Skip to main content

Table 2 Mean baseline and changes from baseline in SPARCC MRI SIJ and spine scores

From: Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial

Mean (95% CI) MRI/CRP-positive subpopulation Total efficacy population
SPARCC MRI SIJ (n = 102) SPARCC MRI spine (n = 101) SPARCC MRI SIJ (n = 131) SPARCC MRI spine (n = 130)
Baseline 6.2 (4.1–8.2) 4.3 (3.3–5.4) 5.0 (3.3–6.6) 3.5 (2.6–4.3)
Change from baseline to:
Year 1 − 5.0 (− 6.9 to − 3.1) − 1.9 (− 2.8 to − 1.0) − 3.9 (− 5.5 to − 2.4) − 1.3 (− 2.1 to − 0.5)
Year 2 − 4.8 (− 6.9 to – 2.8) − 2.0 (− 2.9 to − 1.1) − 3.8 (− 5.4 to − 2.2) − 1.4 (− 2.2 to − 0.7)
  1. Abbreviations: CRP C-reactive protein, MRI Magnetic resonance imaging, SIJ Sacroiliac joint, SPARCC Spondyloarthritis Research Consortium of Canada
  2. Data for patients in the MRI/CRP-positive subpopulation and total efficacy population with MRI scans available at all time points